Showing results (271-280 of 438) with videos related to

Sort By:
Pageof 44
Pediatric Blood & Cancer|March 12, 2014
ACR Appropriateness Criteria Pediatric Hodgkin LymphomaStephanie A Terezakis, Monika L Metzger, David C Hodgson, et al.
Leukemia & Lymphoma|June 14, 2021
Body mass index and survival of patients with lymphomaDai Chihara, Melissa C Larson, Dennis P Robinson, et al.
Journal of the National Cancer Institute. Monographs|September 1, 2014
Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes ProjectKarin E Smedby, Joshua N Sampson, Jennifer J Turner, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 31, 2022
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical TrialsJesse G Dixon, Çağlar Çağlayan, Dai Chihara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphomaSven de Vos, André Goy, Shaker R Dakhil, et al.
Cancer|June 22, 2021
Surveillance imaging during first remission in follicular lymphoma does not impact overall survivalMax L Goldman, Jimmy J Mao, Christopher S Strouse, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2016
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?Zachariah DeFilipp, Amelia A Langston, Zhengjia Chen, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
The Lancet. Haematology|May 30, 2020
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trialGita Thanarajasingam, John P Leonard, Thomas E Witzig, et al.
Blood Advances|November 8, 2021
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort dataLaurie H Sehn, Mark Hertzberg, Stephen Opat, et al.
Pageof 44